Clinical Trial News Archive - February 2022
February 1, 2022
February 2, 2022
- Mechanism Revealed Behind Loss of Smell with COVID-19
- Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
February 3, 2022
- Research shows human amniotic membrane dramatically decreases vocal cord nerve injuries following thyroid cancer surgery
- New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
- Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi is No Longer Valid
February 4, 2022
- Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
- UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results
- Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
February 7, 2022
- AEYE Health Reports Pivotal Clinical Trial Results of its AI Algorithm for the Autonomous Screening and Detection of More-Than-Mild Diabetic Retinopathy
- Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease
- Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases
February 8, 2022
February 9, 2022
- Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
- FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences
February 10, 2022
- FDA Accepts Dupixent (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
- Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
February 11, 2022
- Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology
- Lilly's Bebtelovimab Receives Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
- Veklury (remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
- Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
February 14, 2022
February 15, 2022
- Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
- FDA Approves Phase 2 Clinical Trial of ENV105 for the Treatment of Prostate Cancer
February 16, 2022
- InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
- Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
- New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
- Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy
February 17, 2022
- Health Canada Authorizes Novavax COVID-19 Vaccine
- Despite Robust Results, Innovent Cholesterol Drug Could Face U.S. Challenges
February 18, 2022
- Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study
- Moderna Expands Its mRNA Pipeline With Three New Development Programs
February 21, 2022
February 22, 2022
February 23, 2022
- Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis
- Sanofi and GSK to Seek Regulatory Authorization for COVID-19 Vaccine
February 24, 2022
February 25, 2022
- Update on FDA Adjustment to Evusheld Dosage Regimen in US
- DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Diseas
February 28, 2022
- AbbVie Seeks New Indication for IMBRUVICA (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
- Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Clinical trial results archive
- 2023
- January, February, March, April, May, June, July, August, September, October
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.